Navigation Links
Cord Blood America Says Outreach Program to OB/GYN Nurses, Insurance Case Workers, Paying Significant Dividends

LAS VEGAS, Sept. 8 /PRNewswire/ -- Cord Blood America, Inc. ( (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life-saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today Dr. Geoffrey John O'Neill, its Medical Director, was interviewed by analyst Francis Gaskins. The interview concerned the Company's outreach program to nurses and case workers on the value of storing umbilical cord blood.

The entire interview is available at:

In the interview, Dr. O'Neill explains the importance of talking to case workers for insurance companies, and OB/GYN nurses about the value of cord blood storage.  "These are the people who are in constant contact with the pregnant patient and her family.  Doctors are often too busy to spend the time on this issue.  No other company has an outreach program like we do and we are very proud of it and its successes."

Prior to joining Cord Blood America, Dr. O'Neill was Laboratory and Scientific/Medical Director for Cryo-Cell International Inc. in Florida and was Laboratory Director for the Bio-Matrix Scientific Group Inc., a San Diego biotech research and development firm in the stem cell sector.  He received a Ph.D. in Immunology from the University of Glasgow, Scotland, and is the author or co-author of more than 75 publications in his field in which he has won a number of significant honors.

About Cord Blood America

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at For investor information, visit


Paul Knopick
E & E Communications

SOURCE Cord Blood America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments
2. Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
3. Cord Blood America Reports 12% Increase in 2010 Second Quarter Revenue
4. China Cord Blood Corporation Announces Cancellation of Nine Million Management Incentive Warrants
5. China Cord Blood Corporation Joins Russell Global Index
6. Progenika Biopharma Grants Grifols World-Wide Distribution Rights for the BLOODCHIP® Genotyping Test for Blood Donors
7. Leading Cord Blood Experts Clarify Their Support of CORD:USE Family Cord Blood Bank
8. Scientists Give the Go-Ahead for Private Storage of Stem Cells From Umbilical Cord Blood
9. Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer
10. Examines High Blood Pressure, or Hypertension, and Blood Pressure Monitors
11. New Promega Maxwell 16 LEV Blood DNA Kit Surpasses Concentration Standards in Less Time
Post Your Comments:
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):